Speciality: Hematology
Description:
A warm welcome to all the medical professionals in this memorable scientific session on the management of venous thromboembolism in patients of general surgery.
Venous thromboembolism is the most common cause of death observed in surgical patients. The risk of venous thromboembolism (VTE) among the population of postoperative patients is heterogeneous and depends on intrinsic patient factors.
The risk is determined by the combination of different factors and features such as the use of prophylaxis, perioperative care, etc which are related to the type of surgery. It is evident that extended use of prophylaxis, early mobilization, and the implication of improved perioperative care can help in reducing the risk of VTE in surgical patients.
Thus, depending on the risk for VTE and major bleeding in surgical patients combined methods of mechanical and pharmacological prophylaxis or only mechanical prophylaxis may be preferred.
Therefore, listen to the webinar, grab the knowledge that is shared and follow HiDoc for more such interesting webinar sessions.
See More Webinars @ Hidoc Webinars
1.
A Win for Molecularly Guided Therapy for Cancer of Unknown Primary
2.
Dual-action mRNA vaccine takes aim at aggressive skin cancer
3.
In early dementia, SSRIs enhance cognition and major depression.
4.
Study indicates that exercise can help colon cancer survivors live as long as matched individuals
5.
Patients face high out-of-pocket costs after incident cancer diagnosis
1.
Unlocking the Potential of Ferrotonia: A New Way to Harness Magnetic Energy
2.
Understanding Acute Myeloid Leukemia (AML) and Its Survival Rates
3.
Unraveling the Mysteries of Lymphoma: A Journey into the Unknown
4.
Interpreting Iron Studies: What Your Blood Results Really Mean
5.
Understanding Waldenstrom Macroglobulinemia - A Comprehensive Guide
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
The Landscape of First-Line Treatment for Urothelial Carcinoma- Further Discussion
2.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
3.
The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management- Further Discussion
4.
Navigating the Complexities of Ph Negative ALL - Part IX
5.
Efficient Management of First line ALK-rearranged NSCLC - Part VI
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation